BRAF V600E変異を有するメラノーマにおけるベムラフェニブによる生存率の改善

Chapmanら（Sun,）がこの問題を研究した。

www.synapsesocial.com/papers/69d7370bf07a12db70b8a5b5 — DOI: https://doi.org/10.1056/nejmoa1103782

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma· 1999 · 761 citations
2. Cancer Statistics, 2010· 2010 · 12,610 citations
3. Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.· 2011 · 13 citations
4. Mutations of the BRAF gene in human cancer· 2002 · 10,652 citations
5. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with <i>BRAF</i> V600E mutation-positive metastatic melanoma.· 2011 · 132 citations